春季银行药品名称NEZAM Afdhal博士作为首席医疗官

StephenW

Spring Bank Pharmaceuticals Names Nezam Afdhal, MD as Chief Medical Officer



MILFORD, Mass., Nov. 9, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced that Nezam Afdhal, MD, will join the Company as Chief Medical Officer, effective November 9, 2015. Dr. Afdhal has been a consultant to the Company since 2011, and has served as the Company's non-executive Chief Medical Officer since 2015.

"I am delighted that Dr. Afdhal has joined the Spring Bank Management Team to lead the next stage of our Company's clinical development strategy," said Martin Driscoll, President and Chief Executive Officer of Spring Bank. "Since 2011, our Company has worked extensively with Dr. Afdhal in the area of liver disease and antiviral drug development.  We look forward to benefiting from his leadership as part of the Spring Bank management team as we advance our lead compound, SB 9200, into Phase 2 clinical trials in Hepatitis B patients in the first half of 2016."     

"I am excited to be joining the Spring Bank Management Team at this important time in the company's evolution as we prepare to advance the development of SB 9200, a potential break-through antiviral compound for the treatment of Hepatitis B (HBV) and RSV," said Dr. Afdhal. "I believe Spring Bank's proprietary Small Molecule Nucleic Acid Hybrid Technology (SMNH) can address a wide array of therapeutic indications, potentially improving the lives of patients worldwide.  As a host immune modulating drug targeting RIG-I and NOD-2, cytosolic proteins that play a role in the body's natural defense against viral infections, we believe SB 9200 has the potential to be a backbone in the evolution of HBV antiviral therapy."

Dr. Afdhal will remain as a Senior Physician at the Liver Center at Beth Israel Deaconess Medical Center in Boston, Massachusetts and Professor of Medicine at Harvard Medical School (Part Time). Dr. Afdhal received his MD degree in 1981 from the Royal College of Surgeons in Ireland and did fellowship training at University College Dublin and at Boston University School of Medicine. His clinical expertise focuses on the management of the complications of liver disease, including cirrhosis and portal hypertension. His research has been in the area of liver fibrosis, Hepatitis B and C and has been national and global lead for many novel therapeutic agents approved for liver disease. Dr. Afdhal has served on multiple State and National and Global advisory boards for liver disease. He has served on the Editorial Board and as a reviewer for multiple scientific journals. He has published more than 300 papers in journals such as New England Journal of Medicine, Gastroenterology, Hepatology, Gut, and Journal of Hepatology, as well as 30 book chapters and two books. He is the US Editor for the Journal of Viral Hepatitis. Dr. Afdhal has spoken nationally and internationally on chronic liver disease and received many awards, including the American Liver Foundation Award for Excellence, a Fulbright Scholarship and the Mitchell Lectureship of the Royal College of Physicians. He is a Fellow of the American Association for the Study of Liver Diseases and a member of the European Association for the Study of the Liver.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of orally bioavailable therapeutics based on its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins or enzymes implicated in various disease states. The Company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. SB 9200 has been designed to selectively activate the host cellular proteins, RIG-I and NOD-2, which have been implicated in the body's immune response to viral infections. Spring Bank believes that SB 9200 can play an important role in antiviral therapy by modulating host immune response to fight viral infections such as HBV, HCV and RSV.

Contact:
Maeve Conneighton
Argot Partners
(212) 600-1902
[email protected]

SOURCE Spring Bank Pharmaceuticals, Inc.

StephenW

春季银行药品名称NEZAM Afdhal博士作为首席医疗官



米尔福德，马萨诸塞，2015年11月9号/新华美通/ - 春季银行制药公司是一家临床阶段的生物技术企业，开发创新疗法对病毒性感染的治疗，今天宣布NEZAM Afdhal博士将加盟公司作为首席医疗官，11月9日生效，2015年Afdhal博士自2011年以来的顾问公司，并自2015年起担任本公司非执行首席医疗官。

“我很高兴Afdhal博士加入了春季银行管理团队，领导我们公司的临床开发战略的下一个阶段，”马丁·斯科尔，总统和春季银行的首席执行官说。 “2011年以来，我公司已在肝病和抗病毒药物开发的面积与Afdhal博士广泛的合作。我们期待着受益于他的领导作为春季银行管理团队的一部分，因为我们推进我们的先导化合物，SB 9200，进入第一阶段第一的2016年上半年在乙肝患者的临床试验“

“我很高兴在公司的发展能够加入春季银行管理团队，在这个重要的时刻，因为我们准备推进SB 9200的发展，为乙型肝炎（HBV）和呼吸道合胞病毒治疗的潜在突破抗病毒化合物， “Afdhal博士说。 “我相信春季银行的专有小分子核酸杂交技术（SMNH）可以解决治疗适应症的范围广泛，有可能提高患者的生活世界各地。作为宿主免疫调节药物靶向RIG-I和NOD-2，细胞内的蛋白质，在身体的抗病毒感染的自然防御作用，但我们认为SB 9200是在乙肝抗病毒治疗的进化主干的潜力。“

Afdhal博士将继续担任在肝病中心​​在贝斯以色列女执事医疗中心在波士顿，马萨诸塞州和医学教授在哈佛医学院（兼职）的高级医生。 Afdhal博士外科医生在爱尔兰皇家学院获得了医学博士学位，1981年，做了研究人员的培训，在都柏林大学和波士顿大学医学院。他的临床专业知识专注于肝病，包括肝硬化和门脉高压并发症的管理。他的研究已经在肝纤维化，肝炎B和C的面积与已经国家和全球主管批准用于肝病许多新颖的治疗剂。 Afdhal博士曾在多个国家与国家和全球顾问委员会的肝脏疾病。他曾担任编辑委员会，并作为审稿多个科学期刊。他发表了300多篇论文在杂志上，如新英格兰医学杂志，消化内科，肝病，肠道和肝脏病杂志，以及30个书籍章节和两本书。他是美国编辑器病毒性肝炎杂志。 Afdhal博士发话了国内和国际上的慢性肝病，并获得许多奖项，其中包括美国肝脏基金会杰出奖，富布赖特奖学金和医生皇家学院的米切尔专场讲座。他是美国协会肝病的研究和欧洲协会为肝脏研究成员的研究员。

关于春季银行制药

春季银行药业是一家临床阶段的生物制药公司从事基于其专有的小分子核酸杂交，或SMNH，化学平台一类新型的口服生物疗法的发现和开发。 SMNH化合物是我们设计选择性地靶向和调节涉及各种疾病状态的特定蛋白质或酶的活性的核酸小片段。该公司正在开发其最先进的SMNH候选产品，SB 9200，用于病毒性疾病的治疗。 SB 9200被设计成选择性地激活宿主细胞蛋白质，RIG-I和NOD-2，这已牵涉在体内的病毒感染的免疫应答。春季银行认为，SB 9200可以通过调节宿主的免疫反应对抗病毒感染如HBV，HCV和呼吸道合胞病毒发挥抗病毒治疗中起重要作用。

联系方式：
梅芙Conneighton
隐语合作伙伴
（212）600-1902
[email protected]

源春银制药公司

ivanich

又来一个